Literature DB >> 18193202

Alpha-1-adrenoceptor subtype selective regulation of connexin 43 expression in rat cardiomyocytes.

Diana Marcela Rojas Gomez1, Jan Sebastian Schulte, Friedrich-Wilhelm Mohr, Stefan Dhein.   

Abstract

Connexin43 (Cx43) is the predominant intercellular gap junction protein in the heart providing intercellular communication for the cell-to-cell transfer of electrical activation. In a previous study, we could show that alpha-adrenoceptor stimulation can affect Cx43 expression and function. We now wanted to elucidate which alpha1-adrenoceptor subtype might be involved. Cultured neonatal rat cardiomyocytes were exposed to various concentrations of phenylephrine (0.1-1,000 nM) for 24 h (n=6). Thereafter, cells were harvested, and after lysis, Cx43 content was determined using sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot. Results were normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Finally, we determined the effect of this treatment on intercellular gap junction conductivity using dual whole-cell voltage clamp. Similarly, we tested the effect of an additional treatment with either 10 nM prazosin or, to assess the subtypes, 10 nM of the alpha(1A)-antagonist RS17053 (n=6), 500 nM of the alpha(1B)-antagonist AH1111OA (n=6), or 50 nM of the alpha(1D)-antagonist BMY7378 (n = 6). Moreover, we incubated the cells for 24 h with the alpha(1A)-adrenoceptor agonist A61603 (10 nM). Phenylephrine led to enhanced Cx43 expression with a pEC50 8.00+/-0.06. The other cardiac connexins, Cx40 and Cx45, as well as GAPDH were not affected. This increase in Cx43 expression resulted in enhanced gap-junction conductance (44+/-4 nS vs 26+/-4 nS). As expected, the increased Cx43 expression could be antagonized by prazosin. Moreover, it was nearly completely inhibited by BMY7378 but was not significantly affected by RS17053. AH1111OA led to a moderate but incomplete inhibition. In contrast, beta-actin expression was also up-regulated by phenylephrine but was inhibited by prazosin or RS17053, while it was not affected by BMY7378 or AH1111OA. About 24 h exposure to the alpha(1A)-adrenoceptor agonist A61603 led to a twofold increase in beta-actin but did not affect Cx43. The low pEC50 value of about 1 nM for noradrenaline reported in our earlier study fits well to the hypothesis of an effect mediated predominantly via alpha(1D)-adrenoceptors, which is further supported by the finding of a nearly complete antagonisation of the phenylephrine effect by BMY7378. Thus, we conclude that cardiac Cx43 expression seems to be regulated via alpha(1)-adrenoceptors predominantly by subtype alpha(1D)-adrenoceptors, while other proteins like beta-actin seem to be regulated via alpha(1A)-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193202     DOI: 10.1007/s00210-007-0244-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

Review 1.  Adrenergic and muscarinic receptors in the human heart.

Authors:  O E Brodde; M C Michel
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

2.  Expression of alpha1-adrenergic receptor subtypes in heart cell culture.

Authors:  H P Luther; S Podlowski; W Schulze; R Morwinski; I Buchwalow; G Baumann; G Wallukat
Journal:  Mol Cell Biochem       Date:  2001-08       Impact factor: 3.396

Review 3.  Structural and functional diversity of connexin genes in the mouse and human genome.

Authors:  Klaus Willecke; Jürgen Eiberger; Joachim Degen; Dominik Eckardt; Alessandro Romualdi; Martin Güldenagel; Urban Deutsch; Goran Söhl
Journal:  Biol Chem       Date:  2002-05       Impact factor: 3.915

Review 4.  Pharmacology of gap junctions in the cardiovascular system.

Authors:  Stefan Dhein
Journal:  Cardiovasc Res       Date:  2004-05-01       Impact factor: 10.787

5.  Altered connexin expression in human congestive heart failure.

Authors:  E Dupont; T Matsushita; R A Kaba; C Vozzi; S R Coppen; N Khan; R Kaprielian; M H Yacoub; N J Severs
Journal:  J Mol Cell Cardiol       Date:  2001-02       Impact factor: 5.000

6.  Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation.

Authors:  Stephan Weng; Melani Lauven; Thomas Schaefer; Lioudmila Polontchouk; Rajiv Grover; Stefan Dhein
Journal:  FASEB J       Date:  2002-05-08       Impact factor: 5.191

7.  Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype.

Authors:  D L Saussy; A S Goetz; K L Queen; H K King; M W Lutz; T J Rimele
Journal:  J Pharmacol Exp Ther       Date:  1996-07       Impact factor: 4.030

8.  Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.

Authors:  R Yoshio; T Taniguchi; H Itoh; I Muramatsu
Journal:  Jpn J Pharmacol       Date:  2001-06

9.  Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5.

Authors:  J W Lomasney; S Cotecchia; W Lorenz; W Y Leung; D A Schwinn; T L Yang-Feng; M Brownstein; R J Lefkowitz; M G Caron
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

10.  Learning the language of cell-cell communication through connexin channels.

Authors:  R Bruzzone
Journal:  Genome Biol       Date:  2001-10-15       Impact factor: 13.583

View more
  8 in total

1.  A simulation study of cellular hypertrophy and connexin lateralization in cardiac tissue.

Authors:  Thomas Seidel; Aida Salameh; Stefan Dhein
Journal:  Biophys J       Date:  2010-11-03       Impact factor: 4.033

Review 2.  Adrenergic control of cardiac gap junction function and expression.

Authors:  Aida Salameh; Stefan Dhein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-12       Impact factor: 3.000

Review 3.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

4.  Effects of metoprolol therapy on cardiac gap junction remodelling and conduction in human chronic atrial fibrillation.

Authors:  S Dhein; S Rothe; A Busch; D M Rojas Gomez; A Boldt; A Reutemann; T Seidel; A Salameh; B Pfannmüller; A Rastan; M Kostelka; F W Mohr
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 5.  Cardiac and neuroprotection regulated by α(1)-adrenergic receptor subtypes.

Authors:  Dianne M Perez; Van A Doze
Journal:  J Recept Signal Transduct Res       Date:  2011-02-21       Impact factor: 2.092

6.  Regulation of gap-junction protein connexin 43 by beta-adrenergic receptor stimulation in rat cardiomyocytes.

Authors:  Yi Xia; Kai-Zheng Gong; Ming Xu; You-Yi Zhang; Ji-Hong Guo; Yao Song; Ping Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

7.  Transforming growth factor-beta type I receptor/ALK5 contributes to doxazosin-induced apoptosis in H9C2 cells.

Authors:  Yi-Fan Yang; Chau-Chung Wu; Wen-Pin Chen; Ming-Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-02       Impact factor: 3.000

8.  Myocardial electrotonic response to submaximal exercise in dogs with healed myocardial infarctions: evidence for β-adrenoceptor mediated enhanced coupling during exercise testing.

Authors:  Carlos L Del Rio; Bradley D Clymer; George E Billman
Journal:  Front Physiol       Date:  2015-02-05       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.